- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01808196
Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.
Study Overview
Status
Intervention / Treatment
Detailed Description
Losartan is a drug that is approved by the United States Food and Drug Administration (FDA) for use in adults and children over 6 years of age who have high blood pressure. Losartan has been safe when administered to patients with normal blood pressure. This medication has not been studied in people with eosinophilic esophagitis or connective tissue disorder. Eosinophils are a type of white blood cell that induces inflammation. Eosinophils with other inflammatory cells produce a protein called TGF-β, which may contribute to part of EoE. Losartan may reduce the amount of this protein and therefore, be a treatment for eosinophilic esophagitis.
You will be in the research study for approximately 4 months. Participation in this research study will involve 9 study visits. Of the 9 study visits, at least 3 visits will take place in the clinic; the other visits may take place over the telephone.
Throughout the study, the following activities will occur:
- A physical and vital signs will be obtained
- There will be two endoscopies performed one at the beginning and one at the end of the study
- Blood will be obtained up to three times
- Pregnancy tests will be performed
- Quality-of-life questionnaires will be completed
This is an open-label trial, which means that if you choose to enroll and you meet screening criteria, you will receive Losartan as a treatment. You will start the study drug at a low dose. It will be increased at vist 3 the 1 month visit. The dose of study drug will be increased depending on your weight and how well you tolerate each dose but will not exceed 100mg of study drug per day. It may be increased or decreased during the study if there are any side effects. If you do not have certain side effects, you will take each dose of the study drug between 21 and 28 days until your next study visit. You will swallow a pill or liquid once or twice a day.
This study will consist of 4 phases: screening, treatment (titration and maintenance), end of treatment, and follow-up. Participants that are between 5 to 18 years of age, as well as the parent or legal guardian will be asked to complete questionnaires of quality-of-life symptom severity questionnaires. Participants between the age of 19 and 21 will also have to fill out these questionnaires, but parents/guardians will not have to fill these out. If you are the parent or caretaker, the only study activity in which you will be involved is the completion of questionnaires about you and your family.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Mason, Ohio, United States, 45040
- Kara Kliewer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed diagnosis of eosinophilic esophagitis.
- Have been on a high dose proton pump inhibitor for at least 8 weeks prior to a diagnostic endoscopy of eosinophilic esophagitis without histologic resolution.
- Agree to maintain the same diet throughout the duration of the study.
If participant is female: meet one of the following criteria:
- Is of non-childbearing potential (pre-menarchal or surgically sterile with documentation)
- Is of childbearing potential with a negative urine pregnancy test at screening.
Exclusion Criteria:
- Past or planned cardiac surgeries.
- Had an aortic root Z-score greater than 3 on a previous echocardiogram.
- Have intolerance to the study agent such as angioedema, IgE-mediated allergy.
- Have renal dysfunction with creatinine in excess of the upper normal limit for age.
- Have another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic syndrome, Churg Strauss vasculitis, eosinophilic granuloma, or a parasitic infection).
- Diagnosed with hepatic insufficiency.
- History of abnormal gastric or duodenal biopsy or documented gastrointestinal (GI) disorders (e.g., Celiac Disease, Crohn's disease or helicobacter pylori infection.), not including chronic gastritis, chronic duodenitis, mucosal eosinophilia or other eosinophilic gastrointestinal disorders.
- Used anti-immunoglobulin E [IgE] mAb, anti-tumor necrosis factor [TNF] mAb, anti-IL-5 agents, or anti-IL-13 within the last six months.
- Used methotrexate, cyclosporine, interferon-α, or other systemic immunosuppressive or immunomodulating agents within the last three months.
- Have a history of a stricture during an endoscopy procedure that prevents passage of the endoscope.
- Taking or plan to take an angiotensin II receptor blocker (ARB) therapy, angiotensin-converting enzyme inhibitor (ACEI), beta blocker therapy (BB), or calcium channel blocker at the screening visit or at any time during the study, or have you been taking any of these medications for the last three months.
- If the participant is female: pregnant or nursing.
- Taking any investigative drug or device study within the last 30 days.
- Had participated in any investigative biologics study within the last three months prior to the study entry.
- Taking or plan to take hydrochlorothiazide, warfarin, cimetidine, phenobarbital, rifampin, or fluconazole.
- If the participant is female: using a medically accepted effective method of birth control.
- Will be able to complete all study procedures including endoscopy.
- Taking or plan to take potassium supplements or salt substitutes containing potassium.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Losartan
Participants with eosinophilic esophagitis receive Losartan daily
|
The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Participants in Histologic Remission at 16 Weeks
Time Frame: 16 weeks after treatment
|
Percent of participants with peak eosinophil count < 15 eosinophils/high power field (remission) in distal and proximal esophagus
|
16 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Peak Eosinophil Count at 16 Weeks
Time Frame: Baseline, 16 weeks after treatment
|
Mean change in peak eosinophil count from baseline
|
Baseline, 16 weeks after treatment
|
Change in Pediatric EoE Symptom Score at 16 Weeks
Time Frame: Baseline, 16 weeks after treatment
|
The PEESS V2.0 questionnaire captures EoE-specific symptoms (dysphagia, GERD, nausea/vomiting, and pain) as reported by parents.
The range for PEESS v2.0 scores is 0 to 100, with a higher score being indicative of more frequent and/or severe symptoms.
Scores were obtained at baseline and 16 weeks.
Change in score is defined as total score at 16 weeks minus total score at baseline.
|
Baseline, 16 weeks after treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: J. Pablo Abonia, M.D., Children's Hospital Medical Center, Cincinnati
- Study Director: Marc E Rothenberg, M.D., Ph.D., Children's Hospital Medical Center, Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Hematologic Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Hypersensitivity
- Esophageal Diseases
- Leukocyte Disorders
- Eosinophilia
- Connective Tissue Diseases
- Eosinophilic Esophagitis
- Esophagitis
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Vasoconstrictor Agents
- Losartan
- Angiotensin II
- Angiotensin Receptor Antagonists
Other Study ID Numbers
- 2012-0106
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Esophagitis
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Esophagitis (EoE) | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
Federico II UniversityRecruitingEsophagitis, EosinophilicItaly
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingEosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal DiseaseUnited States
-
Medical University of GrazRecruiting
-
AQILION ABCompletedEosinophilic Esophagitis (EoE)United Kingdom
-
Regeneron PharmaceuticalsSanofiActive, not recruitingEosinophilic Esophagitis (EoE)United States, Canada
-
ShireTakeda Development Center Americas, Inc.TerminatedEosinophilic Esophagitis (EoE)United States
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
ShireCompleted
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
Clinical Trials on Losartan Potassium
-
Chinese PLA General HospitalTianjin TongRenTang Group Co., Ltd.UnknownProteinuria | GlomerulonephritisChina
-
Organon and CoTerminated
-
National Institute of Diabetes and Digestive and...Johns Hopkins UniversityTerminatedNAFLD - Nonalcoholic Fatty Liver DiseaseUnited States
-
University of South FloridaNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States
-
Steadman Philippon Research InstituteRecruitingKnee Arthroplasty, TotalUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Shaw Cancer CenterSteadman Philippon Research InstituteRecruitingRadiation Induced FibrosisUnited States
-
Hospital General de Niños Pedro de ElizaldeRecruitingUric Acid NephropathyArgentina
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic EsophagitisUnited States